INTRAOCULAR IMPLANTS CONTAINING PROSTAMIDE AND METHODS OF THEIR USE Russian patent published in 2018 - IPC A61F2/14 A61K9/16 A61K47/10 A61K47/34 A61K31/5575 A61P27/06 

FIELD: medicine.

SUBSTANCE: group of inventions refers to the field of medicine, namely, ophthalmology, aims to reduce the eye intraocular pressure (IOP). Biodegradable intraocular implant for reducing IOP contains a matrix of a biodegradable polymer, polyethylene glycol 3350 and a prostamide as an active agent, where the prostamide and polyethylene glycol 3350 are bound with the matrix. Said matrix contains a) poly(D,L-lactide) with a complex ether end group having an intrinsic viscosity of 0.25-0.35 dl / g; b) poly(D,L-lactide) with an acid end group having an intrinsic viscosity of 0.16-0.24 dl / g, and c) poly(D,L-lactide-co-glycolide) with a complex end group having an intrinsic viscosity of 0.16-0.24 dl / g and a molar ratio of D,L-lactide to glycolide of about 75:25. Prostamide is 18 to 22% of the implant by weight. Poly(D,L-lactide) with a complex ether end group is 18 to 22% of the implant by weight. Poly(D,L-lactide) with an acidic end group is 13.5 to 16.5% of the implant by weight. Poly(D,L-lactide-co-glycolide) with a complex ether end group is between 36 and 44% of the implant by weight. Polyethylene glycol 3350 is 3.5 to 6.5% by weight of the implant. Intrinsic viscosity of each of the poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers is determined for a 0.1% solution of said polymer in chloroform at 25°C. Method for reducing intraocular pressure in a mammal eye, a device for delivering of the said eye implant, and a method of manufacturing of the mentioned implant are also provided.

EFFECT: usage of a group of inventions makes it possible to accelerate the biodegradation of an implant with a smaller swelling with the release of an effective amount of bimatoprost at a practically linear or constant rate over an extended period of time.

18 cl, 4 tbl, 7 dwg, 1 ex